Grant Jane
London School of Hygiene and Tropical Medicine, London, UK.
Malar J. 2025 Apr 17;24(1):126. doi: 10.1186/s12936-025-05347-0.
Progress in malaria control will rely on deployment and effective targeting of combinations of interventions, including malaria vaccines and perennial malaria chemoprevention (PMC). Several countries with PMC programmes have introduced malaria vaccination into their essential programmes on immunizations, but empirical evidence on the impact of combining these two interventions and how best to co-implement them are lacking. At the American Society of Tropical Medicine and Hygiene 2023 annual meeting, a stakeholder meeting was convened to identify key policy, operational and research gaps for co-implementation of malaria vaccines and PMC. Participants from 11 endemic countries, including representatives from national malaria and immunization programmes, the World Health Organization, researchers, implementing organizations and funders attended. Identified evidence gaps were prioritized to select urgent issues to inform co-implementation. The output of these activities is a strategic roadmap of priority malaria vaccine and PMC co-implementation evidence gaps, and solutions to address them. The roadmap was presented to stakeholders for feedback at the 2024 Multilateral Initiative on Malaria meeting and revised accordingly. The roadmap outlines four key areas of work to address urgent evidence gaps for co-implementation: (1) support to the global and national policy process, (2) implementation support and research, (3) clinical studies, and (4) modelling. Together, these areas will provide practical guidance on the co-implementation of the interventions, and robust evidence to inform decision-making on how best to design, optimize and scale-up co-implementation in different contexts, including if and in what contexts the co-implementation is cost-effective, and the optimal schedule for co-implementation. This will work towards supporting the policy process on co-implementation of malaria vaccines and PMC, and achieving the most impactful use of available resources for the prevention of malaria in children.
疟疾防控工作的进展将依赖于多种干预措施的有效部署和精准靶向，这些措施包括疟疾疫苗和常年性疟疾化学预防（PMC）。一些实施PMC项目的国家已将疟疾疫苗接种纳入其基本免疫规划，但目前缺乏关于这两种干预措施联合使用的影响以及如何最佳协同实施的实证证据。在美国热带医学与卫生学会2023年年会上，召开了一次利益相关者会议，以确定疟疾疫苗和PMC协同实施方面的关键政策、操作和研究差距。来自11个疟疾流行国家的参会者出席了会议，包括国家疟疾和免疫规划的代表、世界卫生组织、研究人员、实施机构和资助者。对已确定的证据差距进行了优先排序，以选择紧迫问题为协同实施提供参考。这些活动的成果是一份关于疟疾疫苗和PMC协同实施证据差距的优先事项战略路线图以及解决这些差距的方案。该路线图在2024年疟疾多边倡议会议上提交给利益相关者征求反馈意见，并据此进行了修订。该路线图概述了四个关键工作领域，以解决协同实施方面的紧迫证据差距：（1）支持全球和国家政策进程；（2）实施支持与研究；（3）临床研究；（4）建模。这些领域将共同为干预措施的协同实施提供实用指导，并为如何在不同背景下最佳设计、优化和扩大协同实施提供有力证据，包括协同实施在何种情况下具有成本效益以及最佳协同实施时间表。这将有助于支持疟疾疫苗和PMC协同实施的政策进程，并最有效地利用现有资源预防儿童疟疾。
